Targeting the CD47-SIRPα immune checkpoints has emerged as a promising strategy in both preclinical and clinical studies, with the potential to modify the tumor microenvironment, restore innate and adaptive immune functions, and enhance the prognosis of gliomas [47]. This evidence concerns the gene CD47 and neoplasm.